Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg) Oct 20, 2023
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer Oct 18, 2023
Fortress Biotech Subsidiary Helocyte Announces Option Agreement with City of Hope for Exclusive Worldwide Rights to use a Novel Bispecific CMV/HIV CAR T Cell Therapy (optionally in combination with Triplex) for the Treatment of Adults Living with HIV-1 Oct 16, 2023
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds Oct 02, 2023
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference Sep 06, 2023
